Prescribing information



Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1

Aimovig is specifically designed to stop migraine before it starts2,3



Play the Aimovig mechanism of action video below to see how it is believed to work in migraine.



Aimovig is the first licensed CGRP receptor antagonist in the UK, specifically designed to prevent migraine across the spectrum*1,4

Graphic illustrating the mechanism of action of Aimovig.

Aimovig is 100% human and binds potently and selectively to the CGRP receptor, blocking its activation1


Preview image. Your guide to Aimovig.

Your guide to Aimovig

A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.



Aimovig injection training video

Watch this injection video for guidance on how to administer Aimovig.

CGRP, calcitonin gene related peptide; Ig, immunoglobulin.


  1. Aimovig® (erenumab) Summary of Product Characteristics.
  2. Aimovig Core Data Sheet v2.5.
  3. Garg S, et al. Anaesthesiology 2020;36(1):104–109.
  4. Bigal ME, et al. Headache 2013;53(8):1230–1244.
Rate this content: 
Average: 4 (1 vote)
UK | August 2023 | 287585

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]